Detailed contribution information

Back to list

Contribution title Efficacy and Safety of Lebrikizumab is Maintained to Two Years in Patients with Moderate-to-Severe Atopic Dermatitis
Authors
  1. Emma Guttman-Yassky 1Icahn School of Medicine at Mount Sinai, New York, NY
  2. Stephan Weidinger University Hospital Schleswig-Holstein
  3. Eric Simpson Oregon Health & Science University
  4. Melinda Gooderham SKiN for Dermatology, Probity Medical Research and Queen’s University, Peterborough
  5. Alan Irvine Children’s Health Ireland
  6. Lynda Spelman Veracity Clinical Research
  7. Jonathan I. Silverberg George Washington University School of Medicine and Health Sciences
  8. Louise DeLuca-Carter Eli Lilly and Company
  9. Laia Bardolet Almirall S.A.
  10. Diamant Thaçi Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck Presenter
Form of presentation Poster
Topic
  • 1.1 Inflammatory and immune-mediated dermatoses